Related Experiment Video
Updated: May 4, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
[New oral anticoagulants: who really needs them?]
1Klinik für Innere Medizin und Geriatrie, Evangelisches Krankenhaus Bielefeld (EvKB), Schildescher Str. 99, 33611, Bielefeld, Deutschland, heiner.berthold@evkb.de.
Abstract:
The new oral anticoagulants (NOAC) are alternative drugs to classical vitamin K antagonists (VKA) for stroke prevention in patients with nonvalvular atrial fibrillation. They have been shown in randomized trials to be superior to warfarin in reducing clinical endpoints, although at rather small effect sizes. However, in study centers with good anticoagulation management their superiority was barely significant. The effectiveness of anticoagulation therapy is crucially dependent on individual drug adherence. NOAC potentially decrease adherence due to several reasons, among them the twice-daily dosing requirement in some of them and the nonnecessity for anticoagulation monitoring. Anticoagulation monitoring is assumed to increase adherence per se. VKA are potentially better suitable to compensate for low adherence due to their long half-lives.
Insights
New oral anticoagulants (NOAC) offer stroke prevention for atrial fibrillation but may reduce adherence due to dosing and lack of monitoring. Vitamin K antagonists (VKA) might better manage adherence issues.
Area of Science:
- Pharmacology
- Cardiology
- Internal Medicine
Context:
- Nonvalvular atrial fibrillation (NVAF) necessitates stroke prevention.
- New oral anticoagulants (NOAC) are alternatives to vitamin K antagonists (VKA).
- Randomized trials show NOAC superiority over warfarin in reducing clinical endpoints, albeit with small effect sizes.
Purpose:
- To evaluate the adherence and effectiveness of NOAC compared to VKA in stroke prevention for NVAF patients.
- To analyze factors influencing anticoagulation therapy effectiveness, including drug adherence and monitoring.
Summary:
- NOAC effectiveness is comparable to VKA, but superiority is diminished in centers with optimal anticoagulation management.
- Adherence is critical for anticoagulation efficacy; NOAC may pose adherence challenges due to twice-daily dosing and lack of routine monitoring.
- Vitamin K antagonists (VKA) may offer advantages in compensating for suboptimal adherence due to their longer half-lives.
Impact:
- Understanding adherence factors is crucial for optimizing stroke prevention strategies in NVAF.
- This research informs clinical practice regarding the choice between NOAC and VKA, considering patient adherence and monitoring capabilities.
- Highlights the importance of patient adherence and monitoring in achieving effective anticoagulation therapy outcomes.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Venous Thrombosis III: Interprofessional Care
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...